Metadoxine
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Metadoxine is a medication used to increase the clearance of alcohol in patients with chronic alcohol dependancy.
- Generic Name
- Metadoxine
- DrugBank Accession Number
- DB16554
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Metadoxine (DB16554)
- Weight
- Average: 298.295
Monoisotopic: 298.116486308 - Chemical Formula
- C13H18N2O6
- Synonyms
- Pyridoxine mixture with Pyrrolidonecarboxylic Acid
- Pyridoxine pyroglutamate
- External IDs
- 277-913-8
Pharmacology
- Indication
Not Available
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset- Associated Conditions
- Contraindications & Blackbox Warnings
Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Comprehensive & structured drug product infoFrom application numbers to product codes, connect different identifiers through our commercial datasets.Easily connect various identifiers back to our datasets- Active Moieties
Name Kind UNII CAS InChI Key Pyridoxine ionic KV2JZ1BI6Z 65-23-6 LXNHXLLTXMVWPM-UHFFFAOYSA-N Pidolic acid ionic SZB83O1W42 98-79-3 ODHCTXKNWHHXJC-VKHMYHEASA-N
Categories
- Drug Categories
- Acids, Acyclic
- Alcohol Deterrents
- Amino Acids
- Amino Acids, Acidic
- Amino Acids, Cyclic
- Amino Acids, Dicarboxylic
- Amino Acids, Peptides, and Proteins
- Central Nervous System Agents
- Glutamates
- Imines
- Imino Acids
- Pharmaceutical Preparations
- Picolines
- Pyridines
- Pyrrolidines
- Pyrrolidinones
- Vitamin B Complex
- Vitamins
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- EJQ7M98H5J
- CAS number
- 74536-44-0
- InChI Key
- RYKKQQUKJJGFMN-HVDRVSQOSA-N
- InChI
- InChI=1S/C8H11NO3.C5H7NO3/c1-5-8(12)7(4-11)6(3-10)2-9-5;7-4-2-1-3(6-4)5(8)9/h2,10-12H,3-4H2,1H3;3H,1-2H2,(H,6,7)(H,8,9)/t;3-/m.0/s1
- IUPAC Name
- (2S)-5-oxopyrrolidine-2-carboxylic acid; 4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol
- SMILES
- OC(=O)[C@@H]1CCC(=O)N1.CC1=NC=C(CO)C(CO)=C1O
References
- General References
- AIFA: Metadoxil (Metadoxine) Oral Solution, Oral Tablet, and Intramuscular and Intravenous Injection [Link]
- External Links
- ChemSpider
- 103074
- Wikipedia
- Metadoxine
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Treatment Severe Alcoholic Hepatitis 1 4 Recruiting Treatment NAFLD / Pre-Diabetic 1 3 Suspended Treatment Non-Alcoholic Steatohepatitis 1 2 Completed Treatment ADHD Predominantly Inattentive Type / ADHD, Predominantly Inattentive Type 1 2 Completed Treatment ADHD, Predominantly Inattentive Type 1 2 Completed Treatment Alcohol Dependency / Severe alcoholic liver disease 1 2 Completed Treatment Alcoholic Fatty Liver Disease / Alcoholic Hepatitis (AH) 1 2 Completed Treatment Attention Deficit Hyperactivity Disorder (ADHD) 1 2 Completed Treatment Fragile X Syndrome (FXS) 1 2, 3 Completed Treatment Attention Deficit Hyperactivity Disorder (ADHD) / Attention-Deficit/Hyperactivity Disorder, Predominantly Inattentive Type 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, solution Intramuscular; Intravenous Solution Oral Tablet Oral Tablet Oral 500 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source logP -0.95 ChemAxon pKa (Strongest Acidic) 9.4 ChemAxon pKa (Strongest Basic) 5.58 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 4 ChemAxon Hydrogen Donor Count 3 ChemAxon Polar Surface Area 73.58 Å2 ChemAxon Rotatable Bond Count 3 ChemAxon Refractivity 44.11 m3·mol-1 ChemAxon Polarizability 17.12 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created on February 05, 2021 22:09 / Updated on May 05, 2021 20:32